Metformin

Endocrinology and Metabolism Clinics of North America

Volumn 26, Issue 3, 1997, Pages 523-537

  Bell, P M ^a   Hadden, D R ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE; BUFORMIN; CHLORHEXIDINE; CHLORPROPAMIDE; CHOLESTEROL; FATTY ACID; GLUCOSE; GLYCOGEN; GUANIDINE DERIVATIVE; INSULIN; KETONE; LACTIC ACID; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PLASMA PROTEIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRUVIC ACID; SULFONYLUREA DERIVATIVE; SYNTHALIN B; TOLBUTAMIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DIET THERAPY; DRUG HALF LIFE; DRUG MECHANISM; ESSENTIAL HYPERTENSION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPID OXIDATION; LIPOLYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR DISEASE;

SALVIA;

EID: 0030879891     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70265-6     Document Type: Article

References (98)

1. E. Abramson R.A. Arky Treatment of the obese diabetic: A comparative study of placebo, sulphonylurea and phenformin Metabolism 16 1967 204
2. G.E. Allen D.A.D. Montgomery J.A. Weaver Dimethylbiguanidine dans le traitement du diabete sucre Rev Francraise D'Endocrinol Clin 2 1960 1
3. L.O. Almer M. Pandolfi Fibrinolysis and diabetic retinopathy Diabetes 25 suppl2 1976 807
4. F. Anfosso N. Chomiki M.C. Alessi Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2: Metformin inhibits the stimulating effect of insulin J Clin Invest 91 1993 2185
5. C.J. Bailey Metformin revisited: Its actions and indications for use Diabet Med 5 1988 315
6. C.J. Bailey Metformin and intestinal glucose handling Diabetes Metab Rev 11 1995 523
7. C.J. Bailey P.R. Flatt C. Ewan Anorectic effect of metformin in lean and genetically obese hyperglycaemic (ob/ob) mice Arch Int Pharmacodyn Ther 282 1986 233
8. P.M. Bell Clinical significance of insulin resistance Diabet Med 13 1996 504
9. C. Bogardus S. Lillioja B.V. Howard Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in nondiabetic and noninsulin dependent diabetic subjects J Clin Invest 74 1984 1238
10. K. Boyd C. Rogers C. Boreham Insulin, glibenclamide or metformin treatment for non–insulin-dependent diabetes: Heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy Diabetes Res 19 1992 69
11. D.G. Bruce D.J. Chisholm L.H. Storlein Physiological importance of deficiency in early prandial insulin secretion in noninsulin dependent diabetes Diabetes 37 1988 736
12. W.J.H. Butterfield M.J. Whichelow The hypoglycaemic action of phenformin: Effect of phenformin on glucose metabolism in peripheral tissues Diabetes 11 1962 281
13. 12 malabsorption associated with long-term metformin treatment BMJ 280 1988 1214
14. I.W. Campbell J. Chalmers A.M. McBain Metformin: Is its use contraindicated in the elderly? Practical Diabetes 9 1992 51
15. R. Chatrvabarti E.D. Hocking G.R. Fearnley Fibrinolytic effect of metformin in coronary-artery disease Lancet 2 1965 256
16. Y.D.I. Chen A. Golay A.L.M. Swislocki Resistance to insulin suppression of plasma free fatty acid concentrations and stimulation of glucose uptake in noninsulin–dependent diabetes mellitus J Clin Endocrinol Metab 64 1987 17
17. B.F. Clarke L.J.P. Duncan Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics Lancet 1 1968 123
18. A. Consoli N. Nurijhan F. Capani Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM Diabetes 38 1989 550
19. A. Czyzyk B. Lao W. Bartosiewicz The effect of short-term administration of antidiabetic biguanide derivatives on the blood lactate levels in healthy subjects Diabetologia 14 1978 89
20. R.A. De Fronzo N.I.R. Barzilai D.C. Simonson Mechanism of metformin action in obese and lean non–insulin-dependent diabetic subjects J Clin Endocrinol Metab 73 1991 1294
21. R.A. De Fronzo R.C. Bonnadonna E. Ferrannini Pathogenesis of NIDDM: A balanced overview Diabetes Care 15 1992 318
22. R.A. De Fronzo A.M. Goodman the Multicenter Metformin Study Group Efficacy of metformin in patients with noninsulin dependent diabetes mellitus N Engl J Med 333 1995 541
23. M. Dorella M. Giusto V. Da Tos Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin resistant hypertensive patients with normal glucose tolerance J Clin Endocrinol Metab 81 1996 1568
24. B. Elpern Chemistry of the biguanides in diabetes mellitus and obesity: Phenformin hydrochloride as a research tool Ann NY Acad Sci 148 1988 577
25. S.S. Fajans J.A. Moorhouse H. Doorenbos Metabolic effects of phenylethylbiguanide in normal subjects and in diabetic patients Diabetes 9 1960 194
26. C. Fannelli S. Calderone L. Epifano Demonstration of a critical role of free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilisation in humans J Clin Invest 92 1993 1617
27. G.I. Fantus R. Brosseau Mechanism of action of metformin: Insulin receptor and post-receptor effects in vitro and in vivo J Clin Endocrinol Metab 63 1986 898
28. R.G. Firth P.M. Bell H.M. Marsh Postprandial hyperglycaemia in patients with noninsulin dependent diabetes mellitus: Role of hepatic and extrahepatic tissues J Clin Invest 77 1986 1525
29. A. Fontbonne J.M. Cohen M.A. Charles The effect of metformin on the metabolic abnormalities associated with upper body fat distribution Diabetes Care 19 1996 920
30. E. Frank M. Nothmann A. Wagner Ueber synthetisch dargestellte Kiaper mit insulinartiger Wirkung auf den Normalen und diabetischen Organismus Klin Wochenschr 5 1926 2100
31. D. Galuska L.A. Nolte J.R. Zierath Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM Diabetologia 37 1994 826
32. P.J. Grant M.H. Strickland N.A. Booth Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor 1 in type 2 diabetic patients Diabet Med 8 1991 361
33. L.C. Groop R.C. Bonadonna S. Del Prato Glucose and free fatty acid metabolism in non–insulin-dependent diabetes mellitus: Evidence for multiple sites of insulin resistance J Clin Invest 84 1989 205
34. D. Guigliano N. De Rosa G. Di Maro Metformin improves glucose, lipid metabolism and reduces blood pressure in hypertensive obese women Diabetes Care 16 1993 1387
35. D. Guigliano A. Quatraro G. Consoli Metformin for obese, insulin treated diabetic patients: Improvement in glycaemia control and reduction of metabolic risk factors Eur J Clin Pharmacol 44 1993 107
36. D.R. Hadden D.A.D. Montgomery J.A. Weaver Long-term effect of chlorpropamide therapy in maturity onset diabetes Diabetes 11 1962 91
37. L.S. Hermann B. Schersten A. Melander Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination Diabet Med 11 1994 953
38. E. Hesse G. Taubmann Die Wirkung des Biguanide und seiner Derwate auf den Zuckerstoffwechsel Arch Exp Pathol Pharmak 142 1929 290
39. A. Holle W. Managels M. Dreyer Biguanide treatment increases the number of insulin receptor sites on human erythrocytes N Engl J Med 305 1981 563
40. C.B. Hollenbeck P. Johnston B.B. Varasteh Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non–insulin-dependent diabetes by glucose tolerance test criteria Diabetes Metab 17 1991 483
41. R.A. Jackson M.I. Haura J.B. Jaspan Mechanisms of metformin action in non–insulin-dependent diabetes Diabetes 36 1987 632
42. R.J. Jarrett In defence of insulin: A critique of syndrome X Lancet 340 1992 469
43. A.B. Johnson J.M. Webster C.F. Sum The impact of metformin on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients Metabolism 42 1993 1217
44. I. Juhan-Vague I. Alessi P. Vague Increased plasma plasminogen activator inhibitor 1 levels: A possible link between insulin resistance and atherothrombosis Diabetologia 34 1991 457
45. K. Landin L. Tengborn V. Smith Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors J Intern Med 229 1991 181
46. P. Leslie R.T. Jung T.E. Isles Energy expenditure in non–insulin-dependent diabetic subjects on metformin, a sulphonylurea therapy Clin Sci 73 1987 41
47. D. Luft R.M. Schmulling M. Eggstein Lactic acidosis in biguanide-treated diabetics: A review of 330 cases Diabetologia 14 1978 75
48. L.L. Madison R.L. Unger Effect of phenformin on peripheral glucose utilization in human diabetic and nondiabetic subjects Diabetes 9 1960 202
49. F. Meyer M. Ipaktchi H. Clauser Specific inhibition of gluconeogenesis by biguanides Nature 213 1967 203
50. V. Montaguti D. Celin C. Ceredi Efficacy of the long-term administration of metformin in hyperlipidaemic patients Res Clin Forums 1 1979 95
51. D.K. Nagi J.S. Yudkin Effects of metformin on insulin resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects Diabetes Care 16 1993 621
52. M. Natrass K.G.M.M. Alberti Biguanides Diabetologia 14 1978 71
53. M. Natrass P.G. Todd L. Hinks Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity onset diabetics Diabetologia 13 1977 145
54. G. Panzram Mortality and survival in type 2 (non–insulin-dependent) diabetes mellitus Diabetologia 30 1987 123
55. D.P. Patel J.M. Stowers Phenformin in weight reduction of obese diabetics Lancet 2 1964 282
56. D.N. Paton L. Findlay The parathyroids—tetania parathyreopriva: Parts I–VIII Q J Exp Physiol 10 1917 203
57. O. Pedersen O. Hother-Nielsen J. Bak The effects of metformin on adipocyte insulin action and metabolic control in obese subjects with type 2 diabetes Diabet Med 6 1989 249
58. G. Perriello P. Misericordia E. Volpi Acute antihyperglycaemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production Diabetes 43 1994 920
59. J. Pomeranze H. Fujiy G.T. Mouratoff Clinical report of a new hypoglycaemic agent Proc Soc Exp Biol Med 95 1957 193
60. R. Prager G. Schernthaner Insulin receptor binding to monocytes, insulin secretion and glucose tolerance following metformin treatment: Results of a double blind cross-over study in type II diabetics Diabetes 32 1983 1083
61. P.J. Randle P.B. Garland C.N. Hales The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus Lancet 1 1963 785
62. B. Rathke Ueber Biguanid Chem Ber 12 1879 776
63. G.M. Reaven Role of insulin resistance in human disease Diabetes 37 1988 1595
64. A. Riccio S. Del Prato V. De Krewtzenberg Glucose and lipid metabolism in non–insulin-dependent diabetes, effect of metformin Diabetes Metab Rev 17 1991 180
65. A.N. Rigas A.H. Bittles D.R. Hadden Circadian variation of glucose, insulin and free fatty acids during long-term use of oral hypoglycaemic agents in diabetes mellitus BMJ 4 1968 25
66. D.P. Rooney R.D.G. Neely O. Beatty Contribution of glucose/glucose-6-phosphate cycle activity to insulin resistance in type 2 (non–insulin-dependent) diabetes mellitus Diabetologia 36 1993 106
67. N.C. Sambol J. Chiang E.T. Lin Kidney function and age are both predictors of pharmacokinetics of metformin J Clin Pharmacol 35 1994 1094
68. V. Sarabia L. Lam E. Burdett Glucose transport in human skeletal muscle cells in culture: Stimulation by insulin and metformin J Clin Invest 90 1992 1386
69. G. Schafer Guanidines and biguanides Pharmacol Ther 8 1980 275
70. G. Schafer Biguanides: A review of history, pharmacodynamics and therapy Diabetes Metab 9 1983 148
71. C.R. Sirtori C. Pasik Reevaluation of a biguanide, metformin: Mechanism of action and tolerability Pharmacol Res 30 1994 187
72. 13C nuclear magnetic resonance spectroscopy N Engl J Med 322 1990 223
73. G. Skiner The dyslipoproteinaemias of diabetes Atherosclerosis 110 suppl 1994 S27
74. K.H. Slotta R. Tschesche Uber Biguanide II: Die Ulutzuckersenkende Wirkung der Biguanide Chem Ber 62 1929 1398
75. J. Sterne Pharmacology and mode of action of the hypoglycaemic guanidine derivatives Oral Hypoglycaemic Agents: Pharmacology and Therapeutics 1969 Academic Press London 193
76. R.W. Stout Experimental atherosclerosis and diabetes mellitus Diabetes and Atherosclerosis 1992 Kluwer Dordrecht 267
77. M. Stumvoll N. Nurjhan G. Perriello Metabolic effects of metformin in non–insulin-dependent diabetes mellitus N Engl J Med 333 1995 550
78. P. Tessari G. Biolo D. Bruttomesso Effects of metformin treatment on whole body and splanchnic amino acid turnover in mild type 2 diabetes J Clin Endocrinol Metab 79 1994 1553
79. The Working Group on Hypertension Statement on hypertension in diabetes mellitus: Final Report Arch Intern Med 147 1987 830
80. 12 status of patients on long-term metformin therapy BMJ 2 1971 685
81. 12 in diabetic patients treated with phenformin: A comparison with metformin BMJ 3 1973 633
82. R. Turner C. Cull R. Holman for the UK Prospective Diabetes Study Group UK Prospective Diabetes Study 17: A 9-year update of a randomized controlled trial on the effect of improved metabolic control on complications in non–insulin-dependent diabetes mellitus Ann Intern Med 124 1996 136
83. UK Prospective Diabetes Study Group UK Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes. A progressive disease Diabetes 44 1995 1249
84. F.D. Underhill N.R. Blatherwick Hypoglycaemic following parathyroidectomy J Biol Chem 18 1914 87
85. United Kingdom Prospective Diabetes Study Group UK Prospective Diabetes Study VI: Complications in newly diagnosed type 2 patients and their association with different clinical and biochemical risk factors Diabetes Res 13 1990 1
86. United Kingdom Prospective Diabetes Study Group UK Prospective Diabetes Study (UKPDS) VIII: Study design, progress and performance Diabetologia 34 1991 877
87. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non–insulin-dependent diabetes followed for three years BMJ 310 1995 83
88. University Group Diabetes Program A study of the effects of hypoglycaemic agents on vascular complications in patients with adult onset diabetes, V Diabetes 24 suppl 1 1975 65
89. P.H. Vague I. Juhan-Vague M.C. Alessi Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and trigyceride levels in non–diabetic obese subjects Thromb Haemost 57 1987 326
90. C.K. Watanabe Studies in the metabolic changes induced by administration of guanidine bases. 1. Influence of injected guanidine hydrochloride upon blood sugar content J Biol Chem 33 1918 253
91. A.K. Waters D.B. Morgan J.K. Wales Blood lactate and pyruvate levels in diabetic patients treated with biguanides with and without sulphonylureas Diabetologia 14 1978 95
92. E.D. Weinberg Antimicrobial activities of biguanides Ann NY Acad Sci 148 1968 587
93. E.I.M. Widen J.G. Eriksson L.C. Groop Metformin normalises nonoxidative glucose metabolism in insulin-resistant normoglycaemic first-degree relatives of patients with NIDDM Diabetes 41 1992 354
94. N. Wiernsperger J.R. Rapin Metformin-insulin interactions: From organ to cell Diabetes Metab Rev 11 1995 S3
95. D.L. Wingard A. Ferrara E.L. Barrett-Connor Is insulin really a heart disease risk factor Diabetes Care 18 1995 1299
96. N. Wollen C.J. Bailey Inhibition of hepatic gluconeogenesis by metformin Biochem Pharmacol 37 1988 4353
97. M.S. Wu P. Johnston W.H.H. Shen Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients Diabetes Care 13 1990 1
98. H. Yki-Jarvinen Glucose toxicity Endocrine Rev 13 1992 415